Literature DB >> 21509657

A full-length 3D structure for MAPK/ERK kinase 2 (MEK2).

Hao Liang1, Tao Liu, Fangjin Chen, Zhaoqing Liu, Shaojun Liu.   

Abstract

As a pivotal signal pathway, the Ras/Raf/MEK/ERK cascade can be activated by multiple extracellular stimuli and can transmit signals to diverse substrates. It remains to be elucidated how so many different signals can be variously transferred by only two MEK molecules (MEK1 and MEK2). Because of technological limitations the complete structures of the MEKs are still unavailable. Here, we report the full-length structure of MEK2 obtained by homology modeling and molecular dynamics simulations. The simulations show that the N-terminal part of MEK2 is highly flexible and this flexibility may enable MEK2 to interact with ERKs and other ligands in diverse manners that correspond to various upstream signals and downstream consequences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21509657     DOI: 10.1007/s11427-011-4156-z

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  5 in total

Review 1.  The clinical development of MEK inhibitors.

Authors:  Yujie Zhao; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

Review 2.  Targeting drivers of melanoma with synthetic small molecules and phytochemicals.

Authors:  Leah Ray Strickland; Harish Chandra Pal; Craig A Elmets; Farrukh Afaq
Journal:  Cancer Lett       Date:  2015-01-15       Impact factor: 8.679

3.  Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.

Authors:  Sarah E Woodfield; Linna Zhang; Kathleen A Scorsone; Yin Liu; Peter E Zage
Journal:  BMC Cancer       Date:  2016-03-01       Impact factor: 4.430

Review 4.  Phosphorylation Sites in Protein Kinases and Phosphatases Regulated by Formyl Peptide Receptor 2 Signaling.

Authors:  Maria Carmela Annunziata; Melania Parisi; Gabriella Esposito; Gabriella Fabbrocini; Rosario Ammendola; Fabio Cattaneo
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

Review 5.  MEK and the inhibitors: from bench to bedside.

Authors:  Akintunde Akinleye; Muhammad Furqan; Nikhil Mukhi; Pavan Ravella; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-04-12       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.